Anticholinergic drug use and risk for dementia: target for dementia prevention
- 1.2k Downloads
An increasing number of longitudinal cohort studies have identified a risk increase for dementia by the chronic use of drugs with anticholinergic properties. The respective data from the German Study on Aging, Cognition and Dementia in Primary Care Patients (AgeCoDe) also showing risk increase (hazard ratio = 2.081) are reported here. The mechanisms by which the risk increase is transported are still unknown. Irritation of compensated alterations of cholinergic transmission at the pre-dementia stage of Alzheimer’s disease (AD) or acceleration of neuroinflammation by disturbance of the anti-inflammatory effect of cholinergic innervation are discussed. In terms of dementia prevention, centrally acting anticholinergic drugs should be strictly avoided, because of long-term dementia risk increase in addition to acute negative effects on cognition.
KeywordsDementia Risk Anticholinergic drugs
The study was supported by the German Competence Network on Dementia (CND) and by the German Competence Network on Degenerative Dementias (CNDD) funded by the German Federal Ministry for Education and Research (grants: O1GI 0102, 01 GI 0710, 01 GI 0711, 01 GI 0712, 01 GI 0713, 01 GI 0714, 01 GI 0715, 01 GI 0716, 01 GI 0717) and the Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM) grant: V-9909/68502/2008.
Conflict of interest
Frank Jessen has received research grants respectively from, is member of the Advisory Boards of, or draws a fee for speech from the following companies: Pfizer, Esai, Janssen Cilag, Novarits, Talecris, Altana Pharma, Octapharma, Merz, and AC Immune.
Horst Bickel has received research support from Organon and Dr. Wilmar Schwabe and fees for lectures from Bayer, Merz, Lundbeck, Dr. Wilmar Schwabe, and Wyeth.
Siegfried Weyerer has received research grants or draws a fee for speech from the following companies: AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen Cilag, Novartis, Pfizer, and Wyeth.
Wolfgang Maier has received research grants respectively from, is member of the Advisory Boards, or draws a fee for speech from the following companies: AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen Cilag, Lundbeck, Merck, Pfizer, Sanofi Aventis, Schering, and Böhringer.
Moritz Daerr, Karl Broich, Michael Pentzek, Steffi Riedel-Heller, Michael Wagner, Birgitt Wiese, Hendrik van den Bussche, and Hanna Kaduszkiewicz declare that they do not have any conflict of interest.
- 3.Thal LJ, Ferris SH, Kirby L, Block GA, Lines CR, Yuen E, Assaid C, Nessly ML, Norman BA, Baranak CC, Reines SA, Rofecoxib Protocol 078 study group (2005) A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 30:1204–1215CrossRefPubMedGoogle Scholar
- 4.ADAPT Research Group, Martin BK, Szekely C, Brandt J, Piantadosi S, Breitner JC, Craft S, Evans D, Green R, Mullan M (2008) Cognitive function over time in the Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol 65:896–905CrossRefPubMedGoogle Scholar
- 16.Jessen F, Wiese B, Bachmann C, Eifflaender-Gorfer S, Haller F, Kölsch H, Luck T, Mösch E, van den Bussche H, Wagner M, Wollny A, Zimmermann T, Pentzek M, Riedel-Heller SG, Romberg HP, Weyerer S, Kaduszkiewicz H, Maier W, Bickel H, German Study on Aging, Cognition and Dementia in Primary Care Patients Study Group (2010) Prediction of dementia by subjective memory impairment: effects of severity and temporal association with cognitive impairment. Arch Gen Psychiatry 67:414–422CrossRefPubMedGoogle Scholar
- 20.Grothe M, Zaborszky L, Atienza M, Gil-Neciga E, Rodriguez-Romero R, Teipel SJ, Amunts K, Suarez-Gonzalez A, Cantero JL (2010) Reduction of basal forebrain cholinergic system parallels cognitive impairment in patients at high risk of developing Alzheimer’s disease. Cereb Cortex 20:1685–1695CrossRefPubMedGoogle Scholar
- 23.DeKosky ST, Ikonomovic MD, Styren SD, Beckett L, Wisniewski S, Bennett DA, Cochran EJ, Kordower JH, Mufson EJ (2002) Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 51:145–155CrossRefPubMedGoogle Scholar